Advertising & affiliate disclosure

Last updated: June 2026

GLP-1 Scorecard is an independent, reader-supported comparison publication. We grade GLP-1 telehealth providers and make money when readers sign up with some of them. We think you should know exactly how that works — and exactly where it stops.

How we get paid

Some providers are affiliate Partners: if you click through and sign up, they pay us a commission, at no extra cost to you. That revenue funds the grading work and keeps the scorecard free. Providers marked Editorial pay us nothing — we grade them anyway, because a scorecard that only covers paying providers is worthless.

The firewall: commissions vs. the grade

The WeighScore is computed from the same six weighted factors for every provider (see the methodology). A commercial relationship cannot add a single point. What it can affect is promotional emphasis — a highlighted row, a spotlight, how often we feature a provider — and that emphasis is always labeled. Grade independent; emphasis disclosed.

Who we are — and aren't

GLP-1 Scorecard is run by an independent publisher. We are not a pharmacy, prescriber, or telehealth company, and we hold no relationship with any provider or manufacturer beyond standard affiliate agreements. We don't grade every provider in existence — only those we've reviewed.

Not medical advice

Grades are a research starting point, not a prescription. Compounded GLP-1 medications are not FDA-approved finished drug products. Talk to a licensed clinician before starting anything, and verify current pricing and availability on the provider's own site.

Trademarks

Ozempic®, Wegovy® and Rybelsus® are trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. We reference these names only to identify the medications discussed; their use implies no endorsement or affiliation. GLP-1 Scorecard is not affiliated with Novo Nordisk, Eli Lilly, or any other manufacturer.

Questions

Reach us via our about page.